<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597934</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-274</org_study_id>
    <nct_id>NCT01597934</nct_id>
  </id_info>
  <brief_title>Antiviral Efficacy of Switching to ETV Plus TDF</brief_title>
  <official_title>A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Switching to Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will result&#xD;
      in faster and greater antiviral activity and lower rates of resistance emergence over&#xD;
      maintaining Lamivudine(LAM)/Telbivudine(LdT)+Adefovir(ADV) combination in partial responders&#xD;
      to LAM/LdT+ADV rescue therapy.&#xD;
&#xD;
      Earlier switching to combination with the most potent regimen will be more effective to&#xD;
      achieve virologic response(VR) and prevent further resistance emergence.&#xD;
&#xD;
      All subjects will orally take assigned drugs once daily for 48 weeks. All subjects will be&#xD;
      assessed at baseline and every three months thereafter. Evaluations at each visit will&#xD;
      include vital signs, physical examinations, laboratory tests, HBV DNA levels and adverse&#xD;
      events. At baseline and every six months thereafter, serum will be assayed for HBV serology.&#xD;
      Genotypic analysis will be performed at baseline and 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. As TDF has not been approved yet in Korea, current KASL practice guideline generally&#xD;
           recommends to add ADV in LAM-resistant or LdT-resistant patients.&#xD;
&#xD;
        2. However, several local literatures reported a substantial proportion of patients treated&#xD;
           with LAM plus ADV combination therapy showed a persistently inadequate or partial&#xD;
           virologic response('VR') and YMDDm still maintained in spite of under rescue combination&#xD;
           therapy.&#xD;
&#xD;
        3. Due to the unavailability of TDF in Korea, ETV plus ADV combination has being considered&#xD;
           a better salvage therapy with non-overlapping cross-resistance profiles in pts who fail&#xD;
           to LAM plus ADV rescue therapy and local report demonstrated that the rate of VR was&#xD;
           significantly higher with ETV+ADV switching group than LAM+ADV continuation group in&#xD;
           partial responder to LAM plus ADV combination rescue therapy for LAM resistance.&#xD;
&#xD;
        4. Hence, more earlier combination therapy with the most potent Nucleoside and Nucleotide&#xD;
           analogue would be a promising salvage treatment for previous NA treatment failures but&#xD;
           comparative prospective trials are limited.&#xD;
&#xD;
        5. Therefore, this study will investigate the greater effectiveness and safety of switching&#xD;
           to the most potent combination versus maintaining LAM(or LdT) plus ADV and also compare&#xD;
           the rate of VR based on the HBV DNA cut-off level at switching - more than and less than&#xD;
           20,000 IU/mL.&#xD;
&#xD;
      All subjects will orally take assigned drugs once daily for 48 weeks. All subjects will be&#xD;
      assessed at baseline and every three months thereafter. Evaluations at each visit will&#xD;
      include vital signs, physical examinations, laboratory tests, HBV DNA levels and adverse&#xD;
      events. At baseline and every six months thereafter, serum will be assayed for HBV serology.&#xD;
      Genotypic analysis will be performed at baseline and 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who achieve virologic response(HBV DNA &lt; 60 IU/mL, approximately 300 copies/mL) by real-time PCR at Week 48</measure>
    <time_frame>at Week 48</time_frame>
    <description>To compare the proportion of subjects who achieve virologic response(HBV DNA &lt; 60 IU/mL, approximately 300 copies/mL) in switching group(Entecavir plus Tenofovir) with that in maintaining group(Lamivudine/Telbivudine plus Adefovir) by real-time Polymerase chain reaction(PCR) at Week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic efficacy</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>To compare virologic response in switching group(Entecavir plus Tenofovir) with those in maintaining group (Lamivudine/Telbivudine plus Adefovir) at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serologic efficacy</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>To compare serologic response in switching group(Entecavir plus Tenofovir) with those in maintaining group (Lamivudine/Telbivudine plus Adefovir) at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical efficacy</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>To compare biochemical response in switching group(Entecavir plus Tenofovir) with those in maintaining group (Lamivudine/Telbivudine plus Adefovir) at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety issue</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>To compare safety issue in switching group(Entecavir plus Tenofovir) with those in maintaining group (Lamivudine/Telbivudine plus Adefovir) at Week 48 - severity of adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A (Zeffix, Sebivo, Hepsera)</intervention_name>
    <description>Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg</description>
    <arm_group_label>Group A:</arm_group_label>
    <other_name>Zeffix</other_name>
    <other_name>Sebivo</other_name>
    <other_name>Hepsera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B (Baraclude, Viread)</intervention_name>
    <description>Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 20 years of age&#xD;
&#xD;
          2. History of HBsAg positive for more than 6 months&#xD;
&#xD;
          3. History of genotypic resistance to LAM or LdT (YMDDm)&#xD;
&#xD;
          4. Partial responder (HBV DNA ≥ 60 IU/mL) currently receiving antiviral combination&#xD;
             rescue therapy for at least 24 weeks of treatment with LAM+ADV or LdT+ADV&#xD;
&#xD;
          5. Hepatitis B e Antigen(HBeAg)-positive and -negative&#xD;
&#xD;
          6. Compensated liver disease (Child-Pugh A)&#xD;
&#xD;
          7. Signed written informed consent after being instructed about the objective and&#xD;
             procedure of the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of genotypic resistance to ADV&#xD;
&#xD;
          2. Most previous treatment of other than LAM+ADV and LdT+ADV&#xD;
&#xD;
          3. Subjects with Alanine Aminotransferase(ALT) &gt; 10xUpper Limit of normal(ULN)&#xD;
&#xD;
          4. Co-infected with hepatitis C virus(HCV) or HIV&#xD;
&#xD;
          5. Pregnant or lactating woman&#xD;
&#xD;
          6. Subject who needs long-term administration of drugs including immunosuppressive&#xD;
             agents, agents related to high risk in the hepatic/renal toxicity, agents influencing&#xD;
             renal excretion&#xD;
&#xD;
          7. History of liver transplantation or planned for liver transplantation&#xD;
&#xD;
          8. Subject who was diagnosed malignant tumor and has been receiving chemotherapy&#xD;
&#xD;
          9. Subject who has HCC history or who shows potential hepatocellular carcinoma (HCC)&#xD;
             finding such as suspicious region in the radiologic exam(abdominal US or CT) or serum&#xD;
             Alpha Feto Protein(AFP) elevation&#xD;
&#xD;
         10. Renal Insufficiency (CLcr &lt; 50ml/min based on Cockcroft-Gault equation considering&#xD;
             weight, ages and serum creatinine)&#xD;
&#xD;
         11. Subject who has a liver disease other than chronic hepatitis B (e.g. hemochromatosis,&#xD;
             Wilson's disease, alcoholic liver disease, nonalcoholic fatty liver disease, alpha&#xD;
             1-antitrypsin deficiency etc.)&#xD;
&#xD;
         12. Subject who has a history of hypersensitivity to study drug or its ingredients&#xD;
&#xD;
         13. Subject who is involved in other clinical trial within 60 days prior to study entry&#xD;
&#xD;
         14. Subject who the investigator deems inappropriate to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hoon Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sang Hoon Ahn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Partial virologic response</keyword>
  <keyword>YMDD mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

